Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.
NSCLC|Ovarian Cancer|Melanoma|Other Solid Tumors
DRUG: LXH254|DRUG: PDR001
Safety and tolerability as assessed by incidence and severity of adverse events (AEs), dose interruptions, reductions, and dose intensity., cycle = 28 days, From Cycle 1 Day 1 until 30 days for LXH254 single agent and 150 days for LXH254 in combination with PDR001 post study treatment (expected duration approximately 12 months)|Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 single agent only), cycle = 28 days, 28 days|Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 in combination with PDR001 only), cycle =28 days, 56 days
Overall response rate (ORR), cycle = 28 days, Every 2 cycles after starting study treatment until end of treatment; expected duration approximately 12 months|Disease control rate (DCR), cycle = 28 days, Every 2 cycles after starting study treatment until end of treatment; expected duration approximately 12 months|Duration of response (DoR), cycle = 28 days, Every 2 cycles after starting study treatment until end of treatment; expected duration approximately 12 months|Progression-free survival (PFS), cycle = 28 days, Every 2 cycles after starting study treatment until disease progression; expected duration approximately 12 months|Overall survival (OS) - only for dose expansion, cycle = 28 days, From time of start treatment until the date of death; expected duration approximately 12 months|Plasma concentrations of LXH254, cycle = 28 days, Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1|Derived PK parameters of LXH254: Area Under the Curve (AUC), cycle = 28 days, Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1|Derived PK parameters of LXH254: Peak Plasma Concentration (Cmax), cycle = 28 days, Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1|Derived PK parameters of LXH254: Time to Peak Plasma Concentration (Tmax), cycle = 28 days, Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1|Derived PK parameters of LXH254: half-life (T1/2), cycle = 28 days, Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1|Changes from baseline of pharmacodynamics (PD) marker DUSP6 in tumor tissue and in blood, cycle = 28 days, Cycle 1 day 1, 2, 3, 15, and 16; upon disease progression (expected duration approximately 12 months)|Plasma concentrations of PDR001, cycle = 28 days, Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1|Derived PK parameters of PDR001: Area Under the Curve (AUC), cycle = 28 days, Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1|Derived PK parameters of PDR001: Peak Plasma Concentration (Cmax), cycle = 28 days, Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1|Derived PK parameters of PDR001: Time to Peak Plasma Concentration (Tmax), cycle = 28 days, Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1|Derived PK parameters of PDR001: half-life (T1/2), cycle = 28 days, Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1
A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.